Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma

Dolly G. Aguilera, Steward Goldman, Jason Fangusaro*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Relapsed/refractory medulloblastoma (MB) has a poor outcome regardless of the treatment employed. Novel therapies are needed in an effort to improve survivals. We present two children with recurrent/refractory MB treated with bevacizumab and irinotecan both given every 2 weeks. One patient also received temozolamide. The first patient had stable disease and remains without progression after 30 months. The second patient had a near complete response that was sustained for 18 months. The regimen was well tolerated with minimal toxicity and provided prolonged progression-free survival in these two patients. Prospective clinical trials are needed to evaluate the effectiveness of this strategy.

Original languageEnglish (US)
Pages (from-to)491-494
Number of pages4
JournalPediatric Blood and Cancer
Issue number3
StatePublished - Mar 2011


  • Bevacizumab
  • Irinotecan
  • Medulloblastoma
  • Recurrent

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma'. Together they form a unique fingerprint.

Cite this